ArticleWorld journal of clinical cases2025
Efficacy and safety of
Article in World journal of clinical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Reprogramming of the mToxics · 2026Article
- Article
- Glycoside Compounds from Blood-Nourishing Chinese Medicinal Herbs: Structural Characteristics, Pharmacological Mechanisms, and Therapeutic Potential for Thrombocytopenia.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatic immune diseases are a group of chronic inflammatory diseases characterized by joint and systemic multi-organ involvement, including rheumatoid arthritis, systemic lupus erythematosus, and Sjogren's syndrome, among others. The pathogenesis of these diseases is related to the abnormal activation and regulatory imbalance of the immune system. The prevalence and morbidity of rheumatic immune diseases are high, imposing a significant burden on patients' quality of life and socio-economic costs. Currently, the treatment of rheumatic immune diseases mainly relies on Western medicine, such as non-steroidal anti-inflammatory drugs, glucocorticoids, disease-modifying antirheumatic drugs, and biologics. However, the therapeutic effects of Western medicine are not ideal, some patients poorly respond or are resistant to Western medicine, and long-term use often causes various adverse reactions.
aimTo systematically evaluate the efficacy and safety of
methodsThis study conducted a meta-analysis to systematically evaluate the efficacy and safety of
resultsThe meta-analysis included 11 RCTs involving 1026 patients with rheumatic immune diseases. The combined treatment significantly reduced the risk of disease recurrence (relative risk = 1.07, 95% confidence interval: 1.01-1.15,
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.